ArticleBMC infectious diseases2025
Overcoming HPV vaccine hesitancy: insights from a successful school-based vaccination campaign in the Saa health district of Cameroon.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Human Papillomavirus Vaccination: Overcoming Barriers to Hesitancy in the GCC Countries.Oman medical journal · 2026Article
- Pakistan's 2025 HPV Vaccine Phase I Rollout: Community Response, Implementation Challenges & Way Forward.Vaccines · 2026Article
- Impact of the COVID-19 Pandemic on HPV Vaccination in Low- and Middle-Income Countries: A Scoping Review.Vaccines · 2026Review
- A retrospective study on factors associated with COVID-19 vaccine refusal among individuals aged 15 years and above in the general population of Bamenda I sub-division, Cameroon.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaccination against human papillomavirus (HPV) represents a critical strategy in the global effort to eradicate cervical cancer. Nonetheless, the uptake of HPV vaccination in Cameroon has been slow, resulting in vaccine wastage during a period of constrained global supply. In the Saa health district, factors such as concerns about infertility, fears of COVID-19 infection, and restrictions on HPV awareness initiatives in Catholic churches and schools have been identified as contributors to vaccine hesitancy. This report outlines the observations from a successful impromptu HPV vaccination campaign conducted in the context of this hesitancy within the Saa health district.
methodsThe campaign took place from the 9th to 25th of May 2023 and targeted 853 adolescents aged 9-13 years. A single-dose schedule with Gardasil was used mainly through the school strategy. Community health workers, teachers and priests participated in sensitization activities via door-to-door sensitization for parents, sensitization in schools for students and in churches for faithfuls respectively. Health facilities vaccinated schools in their catchment area. Vaccination data were recorded in routine vaccination registers.
resultsA total of 1321 adolescents (154%) were vaccinated, 48.9% (n = 646) of whom were boys. Thirty-four primary and two secondary schools participated in the campaign. Health workers, teachers and Catholic priests all participated in sensitization activities. No backlash was reported from parents after vaccination.
conclusionThe successful execution of the campaign can be attributed to the active involvement of key stakeholders within the health district. Continuous advocacy for HPV vaccination, even in a climate of vaccine hesitancy, plays a significant role in positively altering perceptions. Recognizing stakeholders and their influence is essential for tailoring strategies aimed at enhancing HPV vaccine uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.